Boston Scientific Q1 FY25: where the revenue came from and where it went
The whole income statement of Boston Scientific for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2025
- Reported
- May 1, 2025
Revenue$4.66B
+21% year over year
Gross profit$3.21B
69% margin
Operating profit$0.92B
20% margin
Net profit$0.67B
14% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 4.66 | 100% | +21% |
| Electrophysiology | 0.73 | 16% | +143% |
| Interventional cardiology | 0.70 | 15% | +7% |
| Global endoscopy | 0.67 | 14% | +5% |
| Peripheral interventions | 0.66 | 14% | +14% |
| Urology & pelvic health | 0.63 | 14% | +23% |
| Cardiac rhythm management | 0.58 | 12% | +1% |
| Watchman | 0.43 | 9% | +24% |
| Neuromodulation | 0.27 | 6% | +6% |
| Cost of revenue | −1.45 | 31% | |
| Gross profit | 3.21 | 69% margin | +0pp |
| SG&A | −1.60 | 34% | −1pp |
| Other | −0.69 | 15% | +0pp |
| Operating profit | 0.92 | 20% margin | +2pp |
| Interest & other costs | −0.12 | ||
| Tax | −0.13 | ||
| Net profit | 0.67 | 14% margin | +2pp |
182 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest